News Novartis pays up to $1 billion for potential eczema drug Piotr Wnuk dermatology, Galapagos, immunology, MOR106, MorphoSys, Novartis 0 Comment Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to Share X Novartis pays up to $1 billion for potential eczema drug https://pharmaphorum.com/news/novartis-increases-its-immunology-footprint-with-1-billion-deal/
dermatology, Galapagos, immunology, MOR106, MorphoSys, Novartis
0 Comment
